<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T20:02:32Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/174260" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/174260</identifier><datestamp>2025-12-04T19:12:02Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478858</setSpec><setSpec>col_2072_478917</setSpec><setSpec>col_2072_478921</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>ERBB2mRNA expression and response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-positive breast cancer</dc:title>
   <dc:creator>Griguolo, Gaia</dc:creator>
   <dc:creator>Brasó Maristany, Fara</dc:creator>
   <dc:creator>González Farré, Blanca</dc:creator>
   <dc:creator>Pascual, Tomás</dc:creator>
   <dc:creator>Chic Ruché, Núria</dc:creator>
   <dc:creator>Saurí, Tamara</dc:creator>
   <dc:creator>Kates, Ronald</dc:creator>
   <dc:creator>Gluz, Oleg</dc:creator>
   <dc:creator>Martínez, Débora</dc:creator>
   <dc:creator>Paré, Laia</dc:creator>
   <dc:creator>Tsvetkova, Vassilena</dc:creator>
   <dc:creator>Pesantez, David</dc:creator>
   <dc:creator>Vidal Losada, Maria Jesús</dc:creator>
   <dc:creator>Adamo, Barbara</dc:creator>
   <dc:creator>Muñoz Mateu, Montserrat</dc:creator>
   <dc:creator>Galván, Patricia</dc:creator>
   <dc:creator>Barberá, Laura</dc:creator>
   <dc:creator>Cuatrecasas Freixas, Miriam</dc:creator>
   <dc:creator>Christgen, Mathias</dc:creator>
   <dc:creator>Kreipe, Hans</dc:creator>
   <dc:creator>Monge Escartín, Inés</dc:creator>
   <dc:creator>Villagrasa, Patricia</dc:creator>
   <dc:creator>Soy Muner, Dolors</dc:creator>
   <dc:creator>Giarratano, Tommaso</dc:creator>
   <dc:creator>Dieci, Maria Vittoria</dc:creator>
   <dc:creator>Conte, Pierfranco</dc:creator>
   <dc:creator>Harbeck, Nadia</dc:creator>
   <dc:creator>Guarneri, Valentina</dc:creator>
   <dc:creator>Prat Aparicio, Aleix</dc:creator>
   <dc:subject>Càncer de mama</dc:subject>
   <dc:subject>Receptors d'hormones</dc:subject>
   <dc:subject>Breast cancer</dc:subject>
   <dc:subject>Hormone receptors</dc:subject>
   <dc:description>Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,</dc:description>
   <dc:date>2021-02-24T16:59:37Z</dc:date>
   <dc:date>2021-02-24T16:59:37Z</dc:date>
   <dc:date>2020-07-14</dc:date>
   <dc:date>2021-02-24T16:59:37Z</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>2072-6694</dc:identifier>
   <dc:identifier>https://hdl.handle.net/2445/174260</dc:identifier>
   <dc:identifier>704764</dc:identifier>
   <dc:identifier>32674482</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Reproducció del document publicat a: https://doi.org/10.3390/cancers12071902</dc:relation>
   <dc:relation>Cancers, 2020, vol. 12(7), num. 1902</dc:relation>
   <dc:relation>https://doi.org/10.3390/cancers12071902</dc:relation>
   <dc:relation>info:eu-repo/grantAgreement/EC/H2020/847912/EU//RESCUER</dc:relation>
   <dc:rights>cc-by (c) Griguolo, Gaia et al., 2020</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/3.0/es</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>15 p.</dc:format>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>MDPI</dc:publisher>
   <dc:source>Articles publicats en revistes (Medicina)</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>